Search Results - "FOLLENZI, A"

Refine Results
  1. 1

    Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors by Follenzi, A, Sabatino, G, Lombardo, A, Boccaccio, C, Naldini, L

    Published in Human gene therapy (20-01-2002)
    “…Safe and efficient genetic modification of liver cells could enable new therapies for a variety of hepatic and systemic diseases. Lentiviral vectors are…”
    Get more information
    Journal Article
  2. 2
  3. 3

    Generation of β cell‐specific human cytotoxic T cells by lentiviral transduction and their survival in immunodeficient human leucocyte antigen‐transgenic mice by Babad, J., Mukherjee, G., Follenzi, A., Ali, R., Roep, B. O., Shultz, L. D., Santamaria, P., Yang, O. O., Goldstein, H., Greiner, D. L., DiLorenzo, T. P.

    Published in Clinical and experimental immunology (01-03-2015)
    “…Summary Several β cell antigens recognized by T cells in the non‐obese diabetic (NOD) mouse model of type 1 diabetes (T1D) are also T cell targets in the human…”
    Get full text
    Journal Article
  4. 4

    Transplantation of endothelial cells corrects the phenotype in hemophilia A mice by KUMARAN, V., BENTEN, D., FOLLENZI, A., JOSEPH, B., SARKAR, R., GUPTA, S.

    Published in Journal of thrombosis and haemostasis (01-09-2005)
    “…Background: The deficiency of factor VIII, a co‐factor in the intrinsic coagulation pathway results in hemophilia A. Although FVIII is synthesized largely in…”
    Get full text
    Journal Article
  5. 5
  6. 6
  7. 7

    Advanced cell‐based modeling of the royal disease: characterization of the mutated F9 mRNA by Martorell, L., Luce, E., Vazquez, J.L., Richaud‐Patin, Y., Jimenez‐Delgado, S., Corrales, I., Borras, N., Casacuberta‐Serra, S., Weber, A., Parra, R., Altisent, C., Follenzi, A., Dubart‐Kupperschmitt, A., Raya, A., Vidal, F., Barquinero, J.

    Published in Journal of thrombosis and haemostasis (01-11-2017)
    “…Essentials The Royal disease (RD) is a form of hemophilia B predicted to be caused by a splicing mutation. We generated an iPSC‐based model of the disease…”
    Get full text
    Journal Article
  8. 8

    Advanced cell‐based modeling of the royal disease: characterization of the mutated F9mRNA by Martorell, L., Luce, E., Vazquez, J.L., Richaud‐Patin, Y., Jimenez‐Delgado, S., Corrales, I., Borras, N., Casacuberta‐Serra, S., Weber, A., Parra, R., Altisent, C., Follenzi, A., Dubart‐Kupperschmitt, A., Raya, A., Vidal, F., Barquinero, J.

    Published in Journal of thrombosis and haemostasis (01-11-2017)
    “…Essentials The Royal disease (RD) is a form of hemophilia B predicted to be caused by a splicing mutation. We generated an iPSC-based model of the disease…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14

    Cross-talk between the proto-oncogenes Met and Ron by FOLLENZI, A, BAKOVIC, S, GUAL, P, STELLA, M, LONGATI, P, COMOGLIO, P

    Published in Oncogene (22-06-2000)
    “…Scatter Factors control a complex genetic program known as 'invasive growth'. HGF (Scatter factor 1) and MSP (Scatter Factor 2) bind to tyrosine kinase…”
    Get full text
    Journal Article
  15. 15

    RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP by Gaudino, G., Follenzi, A., Naldini, L., Collesi, C., Santoro, M., Gallo, K.A., Godowski, P.J., Comoglio, P.M.

    Published in The EMBO journal (01-08-1994)
    “…RON, a cDNA homologous to the hepatocyte growth factor (HGF) receptor gene (MET), encodes a putative tyrosine kinase. Here we show that the RON gene is…”
    Get full text
    Journal Article
  16. 16
  17. 17

    'Advanced' generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo by BONCI, D, CITTADINI, A, ROSS, J. JR, NALDINI, L, PESCHLE, C, COSSU, G, CONDORELLI, G, LATRONICO, M. V. G, BORELLO, U, AYCOCK, J. K, DRUSCO, A, INNOCENZI, A, FOLLENZI, A, LAVITRANO, M, MONTI, M. G

    Published in Gene therapy (01-04-2003)
    “…Efficient gene transduction in cardiomyocytes is a task that can be accomplished only by viral vectors. Up to now, the most commonly used vectors for this…”
    Get full text
    Journal Article
  18. 18

    Lentivectors encoding immunosuppressive proteins genetically engineer pancreatic β-cells to correct diabetes in allogeneic mice by Kojaoghlanian, T, Joseph, A, Follenzi, A, Zheng, J H, Leiser, M, Fleischer, N, Horwitz, M S, DiLorenzo, T P, Goldstein, H

    Published in Gene therapy (01-03-2009)
    “…The effectiveness of genetic engineering with lentivectors to protect transplanted cells from allogeneic rejection was examined using, as a model, type 1…”
    Get full text
    Journal Article
  19. 19
  20. 20

    The proto-oncogene RON is involved in development of epithelial, bone and neuro-endocrine tissues by Gaudino, G, Avantaggiato, V, Follenzi, A, Acampora, D, Simeone, A, Comoglio, P M

    Published in Oncogene (21-12-1995)
    “…We previously showed that the proto-oncogene RON encodes the tyrosine kinase receptor for Macrophage Stimulating Protein (MSP), originally isolated as a…”
    Get more information
    Journal Article